Biotechnology investments have not been easy for venture-capital firms in recent years. So now that the market is finally turning around, it’s no surprise to see firms doubling down on the winners.
The public and private markets of the past decade are littered with biotech startups that failed to develop an initially promising drug. Even for those that did make it to an IPO, it was not unheard of to see a company’s stock fall 90% in a day with bad news.
To read the original article: With IPOs, VCs Doubling Down on Biotech Bets - Wall Street Journal - WSJ.com
